嘉必优公告，股东马涛因个人资金需求，计划于2025年7月29日至2025年10月28日期间，通过集中竞价 方式减持不超过15万股，占公司总股本的0.0891%。马涛先生目前持有公司股份15.74万股，占公司总股 本的0.0935%。 ...

Group 1 - The stock price of Jia Bi You (688089) closed at 25.13 yuan on July 4, 2025, up 0.44% from the previous week [1] - The company's market capitalization is currently 4.23 billion yuan, ranking 93rd out of 169 in the chemical products sector and 3463rd out of 5149 in the A-share market [1] - The company announced a cash dividend of 0.20094 yuan per share, with the record date on July 9, 2025, and the payment date on July 10, 2025, totaling approximately 33.66 million yuan distributed among 167,519,992 shares [1] Group 2 - The company adjusted the upper limit for the second phase of share repurchase from 25.00 yuan to 24.80 yuan per share, effective from July 10, 2025 [2] - As of June 30, 2025, the company has not yet repurchased any shares through its dedicated securities account, with the repurchase plan initially disclosed on January 25, 2025, and an expected amount between 15 million and 30 million yuan [2][3]

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan, proposing a cash dividend of 0.20094 yuan per share, which was approved at the 2024 annual shareholders' meeting on May 29, 2025 [1][2][3]. Dividend Distribution Plan - The cash dividend of 0.20094 yuan per share is inclusive of tax, and the total number of shares eligible for distribution is 167,519,992 after deducting 789,128 shares held in the company's repurchase account from the total share capital of 168,309,120 shares [2][3]. - The company will not issue bonus shares or increase capital reserves, and the remaining undistributed profits will be carried forward to future years [2][3]. Ex-Dividend Date and Payment Date - The relevant dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [3]. Taxation on Dividends - For individual shareholders and securities investment funds, the cash dividend of 0.20094 yuan per share will not be subject to withholding personal income tax at the time of distribution. Tax will be calculated based on the holding period when the shares are sold [5][6]. - For qualified foreign institutional investors (QFIIs), a 10% corporate income tax will be withheld, resulting in an actual cash dividend of 0.18085 yuan per share [6]. - Hong Kong investors will also have a 10% withholding tax applied, with the same actual cash dividend of 0.18085 yuan per share, and they may apply for tax treaty benefits if applicable [6]. Implementation of Dividend Distribution - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders who have registered their shares by the record date [3][7]. - Shares held in the company's repurchase account will not participate in the profit distribution [3].

Core Viewpoint - The legal opinion issued by Beijing Zhonglun Law Firm confirms that the differentiated dividend distribution plan proposed by Jia Biyou Biotechnology (Wuhan) Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6][11][12]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.20094 RMB per share, totaling approximately 33.66 million RMB, calculated on a base of 167,519,992 shares after deducting repurchased shares [9][10]. - The company has repurchased 789,128 shares, and the total share capital is 168,309,120 shares, which affects the calculation of the dividend distribution [10][11]. - The company will not conduct capital reserve transfers or issue bonus shares, with any remaining undistributed profits carried forward to future years [11]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and facts provided by the company, ensuring the accuracy and completeness of the legal opinion [4][5]. - The legal opinion is based on existing laws, regulations, and the company's articles of association, confirming that the differentiated dividend distribution does not violate any legal provisions [6][12]. - The law firm emphasizes that the opinion is solely for the purpose of the differentiated dividend distribution and cannot be used for any other purpose without consent [5][12].

证券代码：688089 证券简称：嘉必优 公告编号：2025-053 嘉必优生物技术（武汉）股份有限公司 关于第二期以集中竞价交易方式回购公司股份的进展公告 一、回购股份的基本情况 2025 年 1 月 24 日，公司召开第四届董事会第二次会议，审议通过了《关于 第二期以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金 和回购专项贷款以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票，并在未来适宜时机用于实施股权激励计划，回购资金总额不低于人民币 1,500 万元（含），不超过人民币 3,000 万元（含），回购价格不超过 25.00 元/股 （含），回购股份的期限为自公司董事会审议通过本次回购方案之日起不超过 12 个 月 。 具 体 内 容 详 见 公 司 于 2025 年 2 月 7 日 在 上 海 证 券 交 易 所 网 站 (www.sse.com.cn)上披露的《嘉必优生物技术（武汉）股份有限公司关于第二期 以集中竞价交易方式回购公司股份的回购报告书》（公告编号：2025-008）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-054 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年年度利润分配 方案的议案》，公司 2024 年度以实施权益分派股权登记日登记的公司总股本扣除 公司回购专用证券账户中股份为基数，向全体股东每股派发现金红利 0.20094 元 调整前回购价格上限：不超过人民币 25.00 元/股（含） 调整后回购价格上限：不超过人民币 24.80 元/股（含） 回购价格上限调整起始日：2025 年 7 月 10 日（公司 2024 年年度权益分 派除权除息日） （含税）。本次权益分派的股权登记日为 2025 年 7 月 9 日，除权除息日为 2025 年 7 月 10 日，具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） 披露的《嘉必优生物技术（武汉）股份有限公司 2024 年年度权益分派实施公告》 （公告编号：2025-052）。 上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、回购股份的基本情况 ...

北京市中伦律师事务所 关于嘉必优生物技术（武汉）股份有限公司 差异化分红事项的 法律意见书 二〇二五年六月 北京市中伦律师事务所 关于嘉必优生物技术（武汉）股份有限公司 差异化分红事项的 法律意见书 致：嘉必优生物技术（武汉）股份有限公司 根据嘉必优生物技术（武汉）股份有限公司（简称"嘉必优"、"公司"）与 北京市中伦律师事务所（简称"本所"）签订的法律服务协议，本所律师接受嘉 必优委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股份回购规则》（以下简称 "《回购规则》"）、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 （以下简称"《回购指引》"）及《上海证券交易所科创板股票上市规则》（以下简 称"《上市规则》"）等相关法律、法规、规章、规范性文件及《嘉必优生物技术 （武汉）股份有限公司章程》（以下简称"《公司章程》"）的规定，就公司 2024 年 年度利润分配所涉及的差异化分红（以下简称"本次差异化分红"）相关事项出 具本法律意见。 对本法律意见的出具，本所律师特作如下声明： （一）本所律师根据《公司法》《证券法》 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-052 嘉必优生物技术（武汉）股份有限公司 2024年年度权益分派实施公告 每股现金红利0.20094元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/9 | 2025/7/10 | 2025/7/10 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 29 日的2024年年度股东大会审议通过。 二、分配方案 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（公 司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 是否涉及差异化分红 ...

Group 1 - The core point of the article is that Jia Bi You plans to acquire 63.2134% of Ouyi Bio for a total consideration of 830.6237 million yuan, which involves both share issuance and cash payment, marking a significant cross-industry merger for the company [1] - The acquisition comes with a high premium rate of 441.23%, with the assessed value of Ouyi Bio's total equity at 1.316 billion yuan, leading to an assessed increment of approximately 1.0728498 billion yuan [1] - Post-acquisition, the company will recognize goodwill of 681.9464 million yuan, which will represent 23.47% of the total assets and 30.28% of the net assets as of the end of September 2024 [1] Group 2 - Ouyi Bio reported a loss of 8.08 million yuan in 2022 but turned profitable in 2023 with a net profit of 30.63 million yuan, which further increased to 43.19 million yuan in the first three quarters of 2024, indicating significant earnings volatility [2] - The transaction includes a commitment from the sellers that Ouyi Bio's cumulative net profit for 2025, 2026, and 2027 will not be less than 270 million yuan, which requires an average annual net profit of 90 million yuan, nearly double the 2023 figure [3] - Jia Bi You will pay 574 million yuan in shares and 256 million yuan in cash for the acquisition, but as of the end of Q1 2025, the company only has 208 million yuan in cash and 54 million yuan in interest-bearing liabilities [3]

Core Viewpoint - The acquisition of 63.2134% of Ouyi Bio by Jiabiyou for 830 million yuan raises concerns about the high goodwill of 682 million yuan, which could impact Jiabiyou's financial performance if Ouyi Bio fails to meet its profit commitments [2][3][4]. Group 1: Acquisition Details - Jiabiyou announced the acquisition of Ouyi Bio, with an assessment value of 1.316 billion yuan and an appraisal premium rate of 441.23% [3]. - The acquisition price of 830 million yuan represents a significant premium, with Jiabiyou planning to acquire Ouyi Bio at a 4.4 times premium [3]. - Following the acquisition, Jiabiyou's goodwill will increase to 682 million yuan, which constitutes 40% of its total assets projected at 1.687 billion yuan by the end of 2024 [3][4]. Group 2: Financial Performance and Risks - Ouyi Bio has committed to achieving a cumulative net profit of 270 million yuan from 2025 to 2027, but as of September 2024, it has only reported a net profit of 43.19 million yuan [8][10]. - Ouyi Bio's financial health is questionable, with a debt ratio exceeding 50% and a continuous increase in accounts receivable, which rose from 63.38 million yuan at the end of 2022 to 111 million yuan by September 2024 [7][8]. - The inventory of Ouyi Bio has also surged, with a value of 72 million yuan by September 2024, reflecting a 51.82% increase from the end of 2023 [8]. Group 3: Market Position and Growth - Jiabiyou has experienced slow growth since its IPO in 2019, with revenue growth primarily in 2022, while net profit has shown a declining trend [4]. - Despite efforts to diversify into pet and beauty sectors, Jiabiyou's core products, ARA and DHA, still account for nearly 90% of its revenue as of 2024 [5]. - Ouyi Bio's sales prices have been declining, yet its gross margin has improved significantly, rising by 10% over three years, surpassing industry averages [9][10].